Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59737 | 0.85 | NNMT (0.36) | NNMTPARP1SIRT3TDP1KDM4E | |
| SCHEMBL5618594 | 0.84 | PARP1 (0.38) | NNMTPARP1SIRT3TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL28544204 | 0.83 | NNMT (0.35) | NNMTPARP1SIRT3TDP1KDM4E | |
| Bromide SCHEMBL9317974 | 0.82 | PARP1 (0.37) | NNMTPARP1SIRT3TDP1KDM4E | |
| SCHEMBL28733526 | 0.82 | GABRP (0.41) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10630450 | 0.82 | PARP1 (0.37) | NNMTPARP1KDM4EALDH1A1HPGD | |
| SCHEMBL28204616 | 0.81 | GABRP (0.36) | NNMTPARP1SIRT3TDP1KDM4E | |
| SCHEMBL2161703 | 0.81 | PARP1 (0.36) | NNMTPARP1KDM4EALDH1A1HPGD | |
| SCHEMBL288795 | 0.81 | ERN1 (0.40) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6607453 | 0.81 | GABRP (0.36) | NNMTPARP1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240423201-A1 | MULTI-TEMPERATURE ZONE MOSQUITO PREVENTION AND CONTROL TABLET | LI WENJIE (CN) | 2024-12-26 | — | — | US | claimed |
| EP-4480307-A1 | PORTABLE ELECTRIC HEATING MOSQUITO REPELLING APPARATUS | Li, Wenjie (CN) | 2024-12-25 | — | — | EP | claimed |
| EP-4480313-A1 | MULTI-TEMPERATURE ZONE MOSQUITO PREVENTION AND CONTROL TABLET | Li, Wenjie (CN) | 2024-12-25 | — | — | EP | claimed |
| US-20240065253-A1 | PORTABLE ELECTRIC HEATING MOSQUITO REPELLING APPARATUS | LI WENJIE (CN) | 2024-02-29 | — | — | US | claimed |
| CN-115473001-B | Battery separator, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-115473001-A | Battery diaphragm, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-101516860-A | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | claimed |
| EP-3324930-B1 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | DFB SORIA LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240423201-A1 | MULTI-TEMPERATURE ZONE MOSQUITO PREVENTION AND CONTROL TABLET | LI WENJIE (CN) | 2024-12-26 | — | — | US | disclosed |
| US-20240423201-A1 | MULTI-TEMPERATURE ZONE MOSQUITO PREVENTION AND CONTROL TABLET | LI WENJIE (CN) | 2024-12-26 | — | — | US | disclosed |
| EP-4480313-A1 | MULTI-TEMPERATURE ZONE MOSQUITO PREVENTION AND CONTROL TABLET | Li, Wenjie (CN) | 2024-12-25 | — | — | EP | disclosed |
| EP-4480313-A1 | MULTI-TEMPERATURE ZONE MOSQUITO PREVENTION AND CONTROL TABLET | Li, Wenjie (CN) | 2024-12-25 | — | — | EP | disclosed |
| CN-102204962-B | Preparation method of itching-relieving mosquito repellent aerogel patch | ZHEJIANG YIDING MEDICAL DRESSING CO LTD | 2013-03-20 | — | — | CN | disclosed |
| US-20120269914-A1 | PLANT EXTRACTS FOR TREATING SKIN DISEASES | EVORIA GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-2411032-A2 | PLANT EXTRACTS FOR TREATING SKIN DISEASES | Evoria GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| CN-102204962-A | Preparation method of itching-relieving mosquito repellent colloid application | ZHEJIANG YIDING MEDICAL DRESSING CO LTD | 2011-10-05 | — | — | CN | disclosed |
| WO-2010108488-A2 | PLANT EXTRACTS FOR TREATING SKIN DISEASES | EVORIA GMBH (DE) | 2010-09-30 | — | — | WO | disclosed |
| CN-101516860-A | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | NNMT 4429/4885PARP1 3259/4885SIRT3 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.